Vera Therapeutics (NASDAQ:VERA) Given New $75.00 Price Target at HC Wainwright

Vera Therapeutics (NASDAQ:VERA) had its target price reduced by HC Wainwright from $90.00 to $75.00 in a research report released on Friday morning,Benzinga reports. They currently have a buy rating on the stock.

Several other equities research analysts have also commented on the stock. TD Cowen reiterated a “buy” rating on shares of Vera Therapeutics in a research note on Tuesday, September 15th. Raymond James Financial reaffirmed a “strong-buy” rating on shares of Vera Therapeutics in a report on Monday, October 26th. JPMorgan Chase & Co. increased their price target on Vera Therapeutics from $76.00 to $83.00 and gave the company an “overweight” rating in a research report on Tuesday, September 8th. Wedbush reiterated a “neutral” rating and set a $34.00 price target on shares of Vera Therapeutics in a report on Monday, August 17th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Vera Therapeutics in a research report on Thursday, October 15th. One investment analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $74.93.

Vera Therapeutics Stock Down 1.2%

Shares of NASDAQ VERA traded down $0.36 during trading on Friday, hitting $29.78. The stock had a trading volume of 2,078,169 shares, compared to its average volume of 1,702,924. The firm has a fifty day moving average of $31.60 and a two-hundred day moving average of $36.68. The company has a market capitalization of $2.15 billion, a PE ratio of -5.05 and a beta of 1.07. The company has a debt-to-equity ratio of 0.18, a current ratio of 10.92 and a quick ratio of 10.92. Vera Therapeutics has a 12 month low of $23.86 and a 12 month high of $56.05.

Vera Therapeutics (NASDAQ:VERA) last released its quarterly earnings results on Thursday, November 5th. The company reported ($1.30) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.62) by $0.32. The firm had revenue of $10.28 million for the quarter, compared to the consensus estimate of $3.42 million. As a group, equities research analysts forecast that Vera Therapeutics will post -6.45 EPS for the current fiscal year.

Insiders Place Their Bets

In other Vera Therapeutics news, CEO Marshall Fordyce sold 18,500 shares of the stock in a transaction dated Tuesday, September 15th. The shares were sold at an average price of $37.00, for a total transaction of $684,500.00. Following the completion of the transaction, the chief executive officer owned 235,244 shares in the company, valued at $8,704,028. This trade represents a 7.29% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 15.90% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of VERA. Allworth Financial LP boosted its holdings in shares of Vera Therapeutics by 66.3% in the third quarter. Allworth Financial LP now owns 1,515 shares of the company’s stock worth $49,000 after acquiring an additional 604 shares during the period. Russell Investments Group Ltd. grew its stake in Vera Therapeutics by 9.6% during the third quarter. Russell Investments Group Ltd. now owns 54,532 shares of the company’s stock valued at $1,761,000 after acquiring an additional 4,797 shares in the last quarter. Eurizon Capital SGR S.p.A. bought a new stake in Vera Therapeutics during the 3rd quarter worth approximately $32,000. Fifth Third Bancorp increased its holdings in Vera Therapeutics by 49.8% during the 3rd quarter. Fifth Third Bancorp now owns 165,245 shares of the company’s stock worth $5,336,000 after acquiring an additional 54,942 shares during the period. Finally, Fulcrum Asset Management LLP bought a new stake in Vera Therapeutics during the 3rd quarter worth approximately $74,000. 99.21% of the stock is owned by institutional investors.

Key Headlines Impacting Vera Therapeutics

Here are the key news stories impacting Vera Therapeutics this week:

• Positive Sentiment: For Q3 2026, Vera reported a loss of $1.30 per share, narrower than the $1.62 consensus loss, and revenue of $10.28 million versus estimates of $3.42 million. The earnings beats are supportive, although the company remained loss-making. Quarterly earnings report
• Positive Sentiment: HC Wainwright cut its price target to $75 from $90 but maintained a Buy rating. Its revised target still implies substantial upside from the cited $29.79 share price, which may offer support to investors. HC Wainwright rating update
• Neutral Sentiment: Vera granted stock options covering 14,900 shares and restricted stock units covering 7,450 shares to three new employees. The awards are a routine hiring incentive, with a small potential dilution effect. Inducement grants announcement
• Negative Sentiment: A valuation-focused article argues VERA may be above fair value after a 148% run, raising the risk that investors take profits or demand stronger progress to justify the share price. Valuation analysis
• Negative Sentiment: Although HC Wainwright remains bullish, its $15 reduction in the target reflects a more cautious view than before and may temper optimism. HC Wainwright rating update

Vera Therapeutics Company Profile

Vera Therapeutics, Inc is a clinical-stage biotechnology company focused on developing treatments for immunological diseases. The company’s research is centered on therapies that target the underlying causes of autoimmune conditions rather than primarily addressing their symptoms.

Vera’s lead product candidate is atacicept, a biologic designed to inhibit the B-cell survival factors BLyS and APRIL. The company has been evaluating atacicept in IgA nephropathy, an autoimmune kidney disease that can lead to progressive loss of kidney function, and has also investigated its potential in other immune-mediated diseases.